drugset / Trial / NCT00333307
Evaluation of the Safety of Relaxin in Preeclampsia
Phase 1
Suspended
18 enrolled
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether different doses of recombinant human relaxin is safe when given to women with severe preeclampsia
Timeline
- Start
- 2006-10
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relaxin | Protein / enzyme biologic | — | Intravenous |